These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34563497)

  • 1. Bromodomains: A novel target for the anticancer therapy.
    Gokani S; Bhatt LK
    Eur J Pharmacol; 2021 Nov; 911():174523. PubMed ID: 34563497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors.
    Gold S; Shilatifard A
    Curr Opin Genet Dev; 2024 Jun; 86():102181. PubMed ID: 38564841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromodomain inhibitors and cancer therapy: From structures to applications.
    Pérez-Salvia M; Esteller M
    Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromodomains: a new target class for drug development.
    Cochran AG; Conery AR; Sims RJ
    Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.
    Li X; Wu Y; Tian G; Jiang Y; Liu Z; Meng X; Bao X; Feng L; Sun H; Deng H; Li XD
    J Am Chem Soc; 2019 Jul; 141(29):11497-11505. PubMed ID: 31246451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
    Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
    J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.
    Markman RL; Webber LP; Nascimento Filho CHV; Reis LA; Vargas PA; Lopes MA; Zanella V; Martins MD; Squarize CH; Castilho RM
    Cell Oncol (Dordr); 2019 Apr; 42(2):143-155. PubMed ID: 30539410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bromodomain: from epigenome reader to druggable target.
    Sanchez R; Meslamani J; Zhou MM
    Biochim Biophys Acta; 2014 Aug; 1839(8):676-85. PubMed ID: 24686119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
    Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
    ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Roles of Bromodomain Proteins in Cancer.
    Boyson SP; Gao C; Quinn K; Boyd J; Paculova H; Frietze S; Glass KC
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomain Histone Readers and Cancer.
    Jain AK; Barton MC
    J Mol Biol; 2017 Jun; 429(13):2003-2010. PubMed ID: 27890782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor.
    Dutra LA; Heidenreich D; Silva GDBD; Man Chin C; Knapp S; Santos JLD
    Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
    Sartor GC; Powell SK; Brothers SP; Wahlestedt C
    J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.